spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

Clicks: 206
ID: 168326
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Francesca Cinti,* Simona Moffa,* Flavia Impronta,* Chiara MA Cefalo, Vinsin A Sun, Gian Pio Sorice, Teresa Mezza, Andrea Giaccari Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy *These authors contributed equally to this work Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients. Keywords: antidiabetic drugs, glycosylated hemoglobin, glycemic control, sodium-glucose cotransporter 2 inhibitors, precision medicine, type 1 diabetes mellitus, type 2 diabetes mellitus, weight reduction 
Reference Key
f2017drugspotlight Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Cinti F;Moffa S;Impronta F;Cefalo CMA;Sun VA;Sorice GP;Mezza T;Giaccari A
Journal digest journal of nanomaterials and biostructures
Year 2017
DOI
DOI not found
URL
https://www.dovepress.com/spotlight-on-ertugliflozin-and-its-potential-in-the-treatment-of-type--peer-reviewed-article-DDDT
Keywords
type 2 diabetes mellitus glycemic control sodium-glucose cotransporter 2 inhibitors precision medicine type 1 diabetes mellitus antidiabetic drugs ertugliflozin pharmacology glycosylated hemoglobin weight reductiontherapeutics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.